L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 8.18 NOK -2.15%
Market Cap: 558.4m NOK

EV/EBITDA
Enterprise Value to EBITDA

-4.5
Current
-2.7
Median
3.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-4.5
=
Enterprise Value
428.6m NOK
/
EBITDA
-95m NOK
EBITDA Growth EV/EBITDA to Growth
NO
L
Lytix Biopharma AS
OSE:LYTIX
Average EV/EBITDA: 15.5
Negative Multiple: -4.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -203 674.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.9
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.7
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -554.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.8
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -615.8 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-29.6
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A